Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma
(Thomson Reuters ONE) -
Oslo 1 July 2016: Targovax today announced that the first patient has been dosed
in a phase Ib/II clinical trial evaluating ONCOS-102 for the treatment of
malignant pleural mesothelioma (MPM), a rare type of cancer in the lining of the
lung, in combination with pemetrexed and cisplatin.
"New therapies are needed to provide better care for patients with mesothelioma,
a highly malignant cancer with poor prognosis" says Dr Magnus Jaderberg, CMO of
Targovax. "This clinical trial will provide data to evaluate the efficacy and
safety of ONCOS-102 in first and second line mesothelioma patients, and we hope
that our immunotherapy can provide additional benefit to chemotherapy, the
existing standard of care.,
"In addition, treating the first patient in the first oncolytic virus trial of
the merged company is of course an exciting moment for Targovax and all its
stakeholders" adds Dr Jaderberg.
The trial is a randomized phase I/II clinical trial of 30 patients, with a phase
Ib safety lead-in cohort of six patients, in first line and second line MPM
patients who are eligible for treatment with pemetrexed and cisplatin. The
trial's main objectives are determination of safety, immune activation at
lesional level and in peripheral blood, clinical response and the correlation
between clinical outcome and the immunological activation. Several
investigational sites in Europe will participate in this study. In addition to
this trial, Targovax plans to initiate three immunotherapy combination trials
with ONCOS-102 and one with its RAS peptide vaccine TG02 during the second half
of 2016.
Malignant mesothelioma is a rare type of cancer often caused by exposure to
asbestos. There are no curative treatments although surgery, chemotherapy and
radiotherapy can sometimes help to improve patient prognosis and life
expectancy. Pemetrexed and cisplatin is the only standard of care chemotherapy
for malignant mesothelioma, but the median PFS/OS (progression-free
survival/overall survival) from the initiation of treatment is only
approximately 12 months.
ONCOS-102 is a purposefully engineered human serotype 5/3 adenovirus coding for
human GM-CSF optimized to induce systemic anti-tumor T cell response in cancer
patients. In a previous Phase I trial, ONCOS-102 treatment induced tumor
specific immune activation both at systemic and lesional level. The immune
activation was associated with clinical benefit.
For further information, please contact:
Gunnar Gårdemyr, CEO
Phone: +46 73 083 77 79
Email: ggardemyr(at)targovax.com
Øystein Soug, CFO
Phone: +47 906 56 525
Email: oystein.soug(at)targovax.com
Arming the patient's immune system to fight cancer
Targovax is a clinical stage immuno-oncology company developing targeted
immunotherapy treatments for cancer patients. Targovax has a broad and
diversified immune therapy portfolio and aims to become a world leader in its
area. The company is currently developing two complementary and highly targeted
approaches in immuno-oncology.
ONCOS - 102 is a virus-based immunotherapy platform based on engineered
oncolytic viruses armed with potent immune-stimulating transgenes targeting
solid tumors. This treatment is designed to reactivate the immune system's
capacity to recognize and attack cancer cells.
TG01 and TG02 are part of a peptide-based immunotherapy platform targeting the
difficult to treat RAS mutations found in more than 85% of pancreatic cancers,
50% of colorectal cancer and 20-30% of all cancers. Targovax is working towards
demonstrating that TG vaccines will prolong time to cancer progression and
increase survival.
These product candidates will be developed in combination with multiple
treatments, including checkpoint inhibitors in several cancer indications.
Targovax also has a number of other cancer immune therapy candidates in the
early stages of development.
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Targovax ASA via GlobeNewswire
[HUG#2024571]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Zecotek: Second Order for Radiation Safety and Homeland SecurityDatum: 01.07.2016 - 07:15 Uhr
Sprache: Deutsch
News-ID 481184
Anzahl Zeichen: 4956
contact information:
Town:
Oslo
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 359 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Targovax recruits the first patient in a trial with the oncolytic virus ONCOS-102 in malignant pleural mesothelioma"
steht unter der journalistisch-redaktionellen Verantwortung von
Targovax ASA (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
